AndroGel Cost in West Virginia 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Does AndroGel Cost in West Virginia in 2026?

AndroGel's retail cash price in West Virginia sits at approximately $510 per month in 2026, matching the AbbVie manufacturer list price. Without insurance or a savings program, patients paying cash at a WV pharmacy will see that full sticker price. However, several discount pathways can bring out-of-pocket costs down substantially, and compounded testosterone gel represents the largest potential saving for patients who qualify.

Retail Pharmacy Cash Price

The $510 monthly figure applies to a standard 75-gram pump dispenser of AndroGel 1.62% supplying a 1.62 mg/actuation concentration. Pharmacies across West Virginia, from Morgantown to Charleston to Huntington, quote prices in that range for a 30-day supply. GoodRx and similar discount aggregators may shave $30 to $60 off that amount at certain chains, but the savings are modest compared to manufacturer or compounded alternatives.

Testosterone itself is a Schedule III controlled substance under the Controlled Substances Act, meaning no pharmacy can dispense it without a valid prescription from a licensed prescriber. DEA scheduling rules apply statewide.

Why List Price and Street Price Match in WV

West Virginia has fewer large pharmacy benefit managers negotiating aggressive rebates at the retail counter compared with higher-population states. The result is that the manufacturer list price and the average retail cash price converge at roughly the same figure. Patients without a discount mechanism bear the full cost.

Does West Virginia Medicaid Cover AndroGel?

West Virginia Medicaid does not cover branded AndroGel for male hypogonadism as of 2026. This is consistent with the coverage policies of many state Medicaid programs, which treat testosterone replacement therapy for hypogonadism as a lower priority relative to other drug classes. Patients relying on West Virginia Medicaid for their pharmacy benefits will need to explore alternative funding mechanisms.

What WV Medicaid Will and Will Not Cover

West Virginia Medicaid's Preferred Drug List, administered through the Bureau for Medical Services, generally excludes brand-name testosterone gel products for standard male hypogonadism. The program may cover testosterone therapy in narrower clinical scenarios, such as documented hypogonadism secondary to a specific organic cause like Klinefelter syndrome or pituitary disease, but coverage is not guaranteed and requires prior authorization in those cases.

Generic testosterone gel (not AndroGel branded) occasionally appears on Medicaid PDLs at the state level in other states, but West Virginia's current formulary does not include it for this indication. Patients should call the WV Bureau for Medical Services at 1-800-642-8589 to confirm current formulary status, since PDLs can update quarterly.

Medicare Part D and AndroGel

Medicare Part D plans vary in their coverage of testosterone gel. Some Part D formularies place testosterone gel on Tier 3 or Tier 4, resulting in copays between $80 and $200 per month depending on the plan. Patients enrolled in both Medicare and West Virginia Medicaid (dual eligibles) still face the same coverage gap because the WV Medicaid wrap-around benefit does not fill in for excluded drugs. The CMS Medicare Part D formulary search tool allows patients to check their specific plan.

Research published in JAMA Internal Medicine documented wide variation in testosterone therapy coverage across state Medicaid programs, with many programs applying restrictive prior authorization criteria that effectively exclude most male hypogonadism patients from coverage. See Baillargeon et al., JAMA Internal Medicine, 2013.

Which Insurance Plans Cover AndroGel in West Virginia?

Commercial insurance coverage for AndroGel in West Virginia depends entirely on the specific plan and formulary. Major carriers operating in the state, including Highmark West Virginia, The Health Plan, and UnitedHealthcare plans sold through the WV exchange, each maintain their own preferred drug lists.

Typical Commercial Coverage Tiers

Most commercial plans that do cover AndroGel place it on a non-preferred brand tier, which means copays of $60 to $150 per fill before the deductible is met. Plans with a high-deductible structure (HDHPs) require the patient to meet the full deductible, often $1,500 to $3,000, before any drug benefit applies.

Employer-sponsored plans in West Virginia with comprehensive pharmacy benefits are more likely to cover testosterone gel, especially when the prescriber submits documentation of confirmed hypogonadism. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy defines biochemical hypogonadism as a morning serum total testosterone below 300 ng/dL on at least two separate measurements. Bhasin et al., Journal of Clinical Endocrinology and Metabolism, 2018 provides the full guideline, and insurers frequently cite it in their coverage criteria.

Prior Authorization Requirements

Prior authorization is standard for AndroGel on most West Virginia commercial plans. Insurers typically require a confirmed diagnosis of hypogonadism, two low morning testosterone lab values, and documentation that the patient is not using testosterone for purposes outside the FDA-approved label. The FDA approved AndroGel for testosterone replacement therapy in adult males with primary or hypogonadotropic hypogonadism. FDA prescribing information for AndroGel is available via the FDA access data portal.

Step therapy is another common hurdle. Some WV insurers require a trial of generic testosterone gel or intramuscular testosterone cypionate before approving branded AndroGel. Testosterone cypionate injections cost roughly $30 to $50 per month out of pocket, which is why some prescribers start there to satisfy step-therapy requirements before switching to gel formulations.

How Does the AbbVie AndroGel Savings Card Work in West Virginia?

The AbbVie myAbbVie Assist savings card can reduce commercial patients' out-of-pocket cost to as little as $0 per prescription fill. West Virginia residents with commercial insurance, including employer-sponsored plans and individual market plans, may qualify. Medicaid and Medicare beneficiaries are excluded from manufacturer savings programs by federal law.

Eligibility and Enrollment

Patients enroll at abbvie.com or by calling AbbVie's patient support line. The card applies at participating pharmacies and reduces the copay or coinsurance the patient owes after the insurer's payment. AbbVie sets an annual maximum benefit that changes year to year; for 2026, patients should verify the current cap during enrollment because AbbVie adjusts program terms annually.

The savings card does not reduce the amount the insurer pays. It functions as a secondary payer covering the patient's cost-share. For patients whose commercial plan places AndroGel on a high-cost tier, the card can close the gap entirely.

What Happens If Insurance Denies Coverage?

If a West Virginia patient's commercial insurer denies the prior authorization, AbbVie's savings card no longer applies because there is no insurer payment to supplement. In that scenario, the patient either pays cash ($510/month) or pursues an appeal. AbbVie also runs a separate patient assistance program, myAbbVie Assist PAP, for uninsured or underinsured patients who meet income criteria. Applications require proof of income and are reviewed individually.

Is Compounded Testosterone Gel Legal in West Virginia?

Compounded testosterone gel is legal in West Virginia when prepared by a licensed 503A compounding pharmacy operating under state Board of Pharmacy oversight and federal USP guidelines. Patients can obtain compounded testosterone gel with a valid prescription from a licensed prescriber.

503A vs. 503B Pharmacies

Federal law draws a line between 503A pharmacies (traditional compounders dispensing patient-specific prescriptions) and 503B outsourcing facilities (larger-scale compounders that can supply to providers without patient-specific prescriptions). West Virginia residents accessing compounded testosterone gel through a telehealth or in-person prescriber will typically use a 503A pharmacy. The FDA's compounding guidance page outlines the distinction.

A 503A pharmacy cannot compound a commercially available drug in identical form if the only reason is to avoid competition with the brand. However, testosterone gel is commonly compounded at concentrations, bases, or delivery formats that differ from the commercial product, which satisfies the differentiation requirement under federal guidance.

Cost of Compounded Testosterone Gel in West Virginia

The average cost of compounded testosterone gel from a WV-licensed 503A pharmacy is approximately $120 per month in 2026. That represents a $390 per month savings compared to retail AndroGel. The trade-off is that compounded products are not FDA-approved, meaning their potency, purity, and sterility are not verified through the FDA's drug approval process.

The FDA's MedWatch program has received reports of compounded testosterone preparations with inconsistent dosing. FDA safety information on compounded drugs notes that quality assurance depends on individual pharmacy practices rather than a standardized approval pathway.

Selecting a Compounding Pharmacy in West Virginia

Patients should verify that a compounding pharmacy holds a current West Virginia Board of Pharmacy license and, ideally, PCAB (Pharmacy Compounding Accreditation Board) accreditation. PCAB-accredited pharmacies undergo independent quality audits. The PCAB directory lists accredited pharmacies by state.

Clinical Evidence Supporting Testosterone Gel Therapy

The case for testosterone replacement therapy in men with confirmed hypogonadism rests on substantial clinical trial data, including the Testosterone Trials (TTrials), a coordinated set of seven randomized placebo-controlled trials conducted at 12 U.S. Sites in men aged 65 and older with a serum testosterone below 275 ng/dL.

The TTrials Results

The TTrials, published in the New England Journal of Medicine in 2016, enrolled 790 men and tested testosterone gel (titrated to achieve levels of 500 to 1,000 ng/dL) against placebo over 12 months. The sexual function trial showed a statistically significant improvement in sexual desire and erectile function scores. Snyder et al., NEJM, 2016 (PMID 26886521) is the primary reference for this dataset.

The physical function sub-trial showed a modest improvement in 6-minute walk distance but did not meet its prespecified primary endpoint for stair-climbing power. The bone mineral density trial, also part of TTrials, found that testosterone gel increased volumetric bone mineral density at the spine and hip compared to placebo. TTrials bone results, NEJM, 2017 provide those specific data.

Endocrine Society Dosing Targets

The 2018 Endocrine Society guideline recommends targeting a mid-normal range serum testosterone of 400 to 700 ng/dL in men receiving testosterone therapy. For AndroGel 1.62%, the starting dose is 40.5 mg (two pump actuations) applied once daily to the upper arms and shoulders. Bhasin et al., JCEM, 2018 states: "We suggest that testosterone therapy in men with age-related decline in testosterone be considered only for men who have both low testosterone levels and symptoms that are attributable to testosterone deficiency."

Monitoring consists of a serum testosterone drawn 14 days after starting or adjusting dose, targeting a value 2 to 8 hours after application. Hematocrit should be checked at baseline, at 3 to 6 months, and annually thereafter. The FDA label requires a black box warning about secondary exposure risk to women and children from skin contact with treated areas. Full prescribing information via FDA access data.

Cardiovascular Considerations

Testosterone therapy's cardiovascular safety profile remains an active area of study. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement in middle-aged and older men with hypogonadism and elevated cardiovascular risk did not result in significantly more major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months. Lincoff et al., NEJM, 2023 reported a MACE rate of 7.0% in the testosterone group vs. 7.3% in the placebo group (hazard ratio 0.96; 95% CI 0.84 to 1.10). However, the testosterone group showed a higher rate of atrial fibrillation, pulmonary embolism, and acute kidney injury, findings that prescribers in West Virginia should discuss with patients before initiating therapy.

The American Heart Association's position on testosterone therapy recommends individualized cardiovascular risk assessment before prescribing.

Can You Get AndroGel via Telehealth in West Virginia?

Telehealth prescribing of AndroGel is permitted in West Virginia as of 2026. The West Virginia Legislature enacted telehealth parity laws that allow licensed physicians and advanced practice providers to prescribe controlled substances via telemedicine under certain conditions, including a prior established relationship or an initial synchronous audio-video visit.

Federal DEA Rules for Telemedicine Controlled Substances

Testosterone is a Schedule III controlled substance. Under the Ryan Haight Act, prescribing a controlled substance via telemedicine historically required an in-person evaluation first. The DEA issued proposed telemedicine rules in 2023 and has extended prior COVID-era flexibilities, allowing registered telehealth providers to prescribe Schedule III substances after a real-time audio-video visit without a prior in-person encounter, provided the prescriber is DEA-registered and the patient is located in a state where the provider is licensed. DEA telemedicine rule update, 2023.

West Virginia residents can therefore use a telehealth TRT platform, complete an online visit, get labs drawn at a local Quest or LabCorp, and receive an AndroGel or compounded testosterone gel prescription mailed to a WV pharmacy. The entire process can be completed without an in-person clinic visit.

What Telehealth TRT Visits Typically Cost in WV

Telehealth TRT consultations in West Virginia range from $75 to $200 for an initial visit, with follow-up visits at $50 to $100. Some platforms bundle lab work and consultations for a flat monthly fee of $150 to $300. When compounded testosterone gel is included, total monthly costs through a telehealth platform often land between $200 and $350, still well below the $510 retail AndroGel cash price.

AndroGel Discount Programs and Cheapest Options in West Virginia

West Virginia patients have four primary pathways to reduce AndroGel or testosterone gel costs, and the right choice depends on insurance status and clinical preference.

Pathway 1: AbbVie Savings Card (Commercially Insured)

Patients with commercial insurance who meet eligibility requirements pay as little as $0 per fill. Enroll at AbbVie's website before the first fill. This is the best option for commercially insured West Virginians whose plan covers AndroGel under prior authorization.

Pathway 2: Compounded Testosterone Gel via 503A Pharmacy (Cash-Pay or Uninsured)

At $120 per month, compounded testosterone gel is the lowest-cost route for patients without usable insurance coverage. A West Virginia-licensed prescriber (in-person or telehealth) writes a prescription specifying the desired concentration and base. The 503A pharmacy compounds and ships or dispenses directly.

Pathway 3: Generic Testosterone Gel (GoodRx or Cash)

Generic testosterone gel 1% (not AndroGel branded) is available at some West Virginia pharmacies at lower cash prices, sometimes $80 to $150 per month with GoodRx. Bioequivalence to AndroGel 1.62% is not guaranteed because the concentrations differ, and dose adjustments may be required. The FDA's generic drug database lists approved generic testosterone gel products. FDA Orange Book confirms approved generics.

Pathway 4: Testosterone Cypionate Injection (Lowest Cost Alternative)

Testosterone cypionate 200 mg/mL injectable costs roughly $30 to $50 per month at West Virginia pharmacies. It is the most cost-effective form of testosterone replacement and is widely covered on WV Medicaid and commercial formularies. Patients who prioritize cost over delivery method should discuss intramuscular or subcutaneous injection with their prescriber. The Endocrine Society guideline notes that intramuscular testosterone cypionate administered every 1 to 2 weeks achieves serum levels within the therapeutic range for most men. Bhasin et al., JCEM, 2018.

Research in the Journal of Clinical Endocrinology and Metabolism found that adherence to testosterone gel therapy was 84% at 6 months compared to 67% for intramuscular injections in a real-world cohort, suggesting that delivery method preference affects long-term treatment success. Kovac et al., JCEM, 2014.

West Virginia patients should obtain a morning serum total testosterone level (drawn between 7 a.m. And 10 a.m.) before initiating any testosterone therapy, per Endocrine Society and American Urological Association guidance. AUA testosterone deficiency guideline, 2022 recommends two separate confirmatory measurements before starting treatment.